使用HER2/EIF2C1比例的微滴数字PCR检测HER2在HER2低表达或模糊表达的FFPE乳腺癌组织中的扩增

{"title":"使用HER2/EIF2C1比例的微滴数字PCR检测HER2在HER2低表达或模糊表达的FFPE乳腺癌组织中的扩增","authors":"","doi":"10.33140/ijcrt.08.02.03","DOIUrl":null,"url":null,"abstract":"Background: HER2 amplification/overexpression is the predictive biomarker for HER2-targeted therapy. The aim of this study is to investigate whether droplet digital PCR (ddPCR) using the HER2/EIF2C1 ratio could be an alternative HER2 detection assay in formalin-fixed, paraffin-embedded (FFPE) BC tissues with low or equivocal HER2 expression. Methods and Patients: We determined HER2 status by ddPCR in 150 FFPE BC tissues previously classified as IHC1+, IHC2+, and IHC3+; 90 of these were previously determined as FISH-negative and FISH-positive. Optimal cutoff thresholds for the HER2/EIF2C1 ratio, determined by the receiver operating characteristics (ROC) curve, were 2.72 (98% sensitivity, 88% specificity) and 2.64 (89.23% sensitivity, 92% specificity) using IHC and FISH as standard methods, respectively. Results: The concordance rate of HER2 status (n=144) determined by IHC/FISH and ddPCR was 89.58% (kappa=0.791, 89.85% sensitivity, 89.33% specificity). The HER2/EIF2C1 ratio in the IHC3+ group was significantly higher than in IHC1+ and IHC2+ groups (P<0.0001). In IHC3+, the concordance between IHC/FISH and ddPCR was 98% (kappa=1.00). In IHC2+ (n=44), the concordance between FISH and ddPCR was 79.54% (kappa=0.579, 65% sensitivity, 91.7% specificity); the HER2/EIF2C1 ratio in FISH-positive cases was significantly higher than in FISH-negative cases (P<0.001). Interestingly, 12% of IHC1+ cases showed HER2 amplification by ddPCR. Conclusion: Thus, ddPCR using the HER2/EIF2C1 ratio is a robust, sensitive, and accurate assay and represents an alternative method to determine HER2 amplification. This technique should be used to clarify HER2 amplification in breast cancer patients with low or equivocal HER2 expression (IHC1+ or IHC2+ with FISH-negative), which may benefit from novel HER2-directed ADCs. The heterogeneity of HER2-expressing cells contributes to discordant results between ddPCR and FISH.","PeriodicalId":310821,"journal":{"name":"International Journal of Cancer Research &amp; Therapy","volume":"32 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Droplet Digital PCR Using HER2/EIF2C1 Ratio for Detection of HER2 Amplification in FFPE Breast Cancer Tissues with Low or Equivocal HER2 Expression\",\"authors\":\"\",\"doi\":\"10.33140/ijcrt.08.02.03\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: HER2 amplification/overexpression is the predictive biomarker for HER2-targeted therapy. The aim of this study is to investigate whether droplet digital PCR (ddPCR) using the HER2/EIF2C1 ratio could be an alternative HER2 detection assay in formalin-fixed, paraffin-embedded (FFPE) BC tissues with low or equivocal HER2 expression. Methods and Patients: We determined HER2 status by ddPCR in 150 FFPE BC tissues previously classified as IHC1+, IHC2+, and IHC3+; 90 of these were previously determined as FISH-negative and FISH-positive. Optimal cutoff thresholds for the HER2/EIF2C1 ratio, determined by the receiver operating characteristics (ROC) curve, were 2.72 (98% sensitivity, 88% specificity) and 2.64 (89.23% sensitivity, 92% specificity) using IHC and FISH as standard methods, respectively. Results: The concordance rate of HER2 status (n=144) determined by IHC/FISH and ddPCR was 89.58% (kappa=0.791, 89.85% sensitivity, 89.33% specificity). The HER2/EIF2C1 ratio in the IHC3+ group was significantly higher than in IHC1+ and IHC2+ groups (P<0.0001). In IHC3+, the concordance between IHC/FISH and ddPCR was 98% (kappa=1.00). In IHC2+ (n=44), the concordance between FISH and ddPCR was 79.54% (kappa=0.579, 65% sensitivity, 91.7% specificity); the HER2/EIF2C1 ratio in FISH-positive cases was significantly higher than in FISH-negative cases (P<0.001). Interestingly, 12% of IHC1+ cases showed HER2 amplification by ddPCR. Conclusion: Thus, ddPCR using the HER2/EIF2C1 ratio is a robust, sensitive, and accurate assay and represents an alternative method to determine HER2 amplification. This technique should be used to clarify HER2 amplification in breast cancer patients with low or equivocal HER2 expression (IHC1+ or IHC2+ with FISH-negative), which may benefit from novel HER2-directed ADCs. The heterogeneity of HER2-expressing cells contributes to discordant results between ddPCR and FISH.\",\"PeriodicalId\":310821,\"journal\":{\"name\":\"International Journal of Cancer Research &amp; Therapy\",\"volume\":\"32 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Cancer Research &amp; Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33140/ijcrt.08.02.03\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Cancer Research &amp; Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33140/ijcrt.08.02.03","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:HER2扩增/过表达是HER2靶向治疗的预测性生物标志物。本研究的目的是研究使用HER2/EIF2C1比值的液滴数字PCR (ddPCR)是否可以作为HER2低表达或模糊表达的福尔马林固定石蜡包埋(FFPE) BC组织中HER2的替代检测方法。方法和患者:我们通过ddPCR检测了150例FFPE BC组织中HER2的状态,这些组织先前被分类为IHC1+、IHC2+和IHC3+;其中90例先前被确定为fish阴性和fish阳性。受试者工作特征(ROC)曲线确定HER2/EIF2C1比值的最佳阈值分别为2.72(灵敏度98%,特异性88%)和2.64(灵敏度89.23%,特异性92%),以IHC和FISH为标准方法。结果:IHC/FISH和ddPCR检测HER2状态(n=144)的符合率为89.58% (kappa=0.791,敏感性89.85%,特异性89.33%)。IHC3+组HER2/EIF2C1比值显著高于IHC1+和IHC2+组(P<0.0001)。在IHC3+中,IHC/FISH与ddPCR的一致性为98% (kappa=1.00)。在IHC2+ (n=44)中,FISH与ddPCR的一致性为79.54% (kappa=0.579,敏感性65%,特异性91.7%);fish阳性组HER2/EIF2C1比值显著高于fish阴性组(P<0.001)。有趣的是,12%的IHC1+病例通过ddPCR显示HER2扩增。结论:因此,使用HER2/EIF2C1比例的ddPCR是一种稳健、敏感和准确的检测方法,是确定HER2扩增的另一种方法。该技术应用于澄清HER2低表达或模棱两可表达(IHC1+或IHC2+ fish阴性)的乳腺癌患者的HER2扩增,这可能受益于新型HER2定向adc。her2表达细胞的异质性导致了ddPCR和FISH结果的不一致。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Droplet Digital PCR Using HER2/EIF2C1 Ratio for Detection of HER2 Amplification in FFPE Breast Cancer Tissues with Low or Equivocal HER2 Expression
Background: HER2 amplification/overexpression is the predictive biomarker for HER2-targeted therapy. The aim of this study is to investigate whether droplet digital PCR (ddPCR) using the HER2/EIF2C1 ratio could be an alternative HER2 detection assay in formalin-fixed, paraffin-embedded (FFPE) BC tissues with low or equivocal HER2 expression. Methods and Patients: We determined HER2 status by ddPCR in 150 FFPE BC tissues previously classified as IHC1+, IHC2+, and IHC3+; 90 of these were previously determined as FISH-negative and FISH-positive. Optimal cutoff thresholds for the HER2/EIF2C1 ratio, determined by the receiver operating characteristics (ROC) curve, were 2.72 (98% sensitivity, 88% specificity) and 2.64 (89.23% sensitivity, 92% specificity) using IHC and FISH as standard methods, respectively. Results: The concordance rate of HER2 status (n=144) determined by IHC/FISH and ddPCR was 89.58% (kappa=0.791, 89.85% sensitivity, 89.33% specificity). The HER2/EIF2C1 ratio in the IHC3+ group was significantly higher than in IHC1+ and IHC2+ groups (P<0.0001). In IHC3+, the concordance between IHC/FISH and ddPCR was 98% (kappa=1.00). In IHC2+ (n=44), the concordance between FISH and ddPCR was 79.54% (kappa=0.579, 65% sensitivity, 91.7% specificity); the HER2/EIF2C1 ratio in FISH-positive cases was significantly higher than in FISH-negative cases (P<0.001). Interestingly, 12% of IHC1+ cases showed HER2 amplification by ddPCR. Conclusion: Thus, ddPCR using the HER2/EIF2C1 ratio is a robust, sensitive, and accurate assay and represents an alternative method to determine HER2 amplification. This technique should be used to clarify HER2 amplification in breast cancer patients with low or equivocal HER2 expression (IHC1+ or IHC2+ with FISH-negative), which may benefit from novel HER2-directed ADCs. The heterogeneity of HER2-expressing cells contributes to discordant results between ddPCR and FISH.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信